| Issue |
Section |
Title |
File |
| Vol 20, No 3 (2018) |
Articles |
The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer |
(Rus)
|
| Vol 21, No 2 (2019) |
Articles |
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience |
(Rus)
|
| Vol 21, No 1 (2019) |
Articles |
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia |
(Rus)
|
| Vol 22, No 1 (2020) |
CLINICAL ONCOLOGY |
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
(Rus)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
(Rus)
(Eng)
|
| Vol 24, No 4 (2022) |
CLINICAL ONCOLOGY |
Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study |
(Rus)
|
| Vol 26, No 1 (2024) |
Articles |
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia |
(Rus)
|
| Vol 26, No 1 (2024) |
Articles |
Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study |
(Rus)
|
| Vol 26, No 4 (2024) |
Articles |
The reasons for prescribing antitumor drugs beyond the registered indications in real clinical practice: A retrospective study |
(Rus)
|
